An update on pathogenesis of psoriatic arthritis and potential therapeutic targets

Chimenti, Maria Sole; Triggianese, Paola; Martino, Erica De; Conigliaro, Paola; Fonti, Giulia Lavinia; Sunzini, Flavia; Caso, Francesco; Perricone, Carlo; Costa, Luisa; Perricone, Roberto

doi:10.1080/1744666x.2019.1627876

Cited by 33 publications

(32 citation statements)

References 189 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, there were no correlations between the serum IL-23 level and either the QoL indices or the HAQ-DI score, despite being positively correlated with disease activity indices. This lack of correlation may be because psoriatic disease (skin and joints) results from an interplay between several pathogenetic mechanisms involving several cytokines, including IL-23 [57][58][59]. All of the cytokines contribute to the disease activity in different degrees.…”

Section: Discussionmentioning

confidence: 99%

Serum Interleukin 23 in Psoriatic Arthritis Patients: Relation to disease activity, physical function and health related quality of life

Elsawy

Helal

Shafei

et al. 2019

Aktuelle Rheumatologie

View full text Add to dashboard Cite

Objective To assess interleukin 23 (IL-23) levels in the sera of psoriatic arthritis (PsA) patients and to determine the relationship of IL-23 with different disease activity indices, physical function and quality of life (QoL). Methods Fifty PsA patients and 46 matched healthy controls were included in this study. Data including a detailed history, a thorough clinical examination, skin severity based on the Psoriasis Area and Severity Index (PASI), the Disease Activity index for Psoriatic Arthritis (DAPSA) and the Composite Psoriatic Disease Activity Index (CPDAI) were obtained for all patients. Physical function was assessed by the Health Assessment Questionnaire Disability Index (HAQ-DI) and health-related QoL was assessed using the Short Form Health Survey (SF-36), Psoriatic Arthritis Quality of Life (PsAQoL) and the Dermatology Life Quality Index (DLQI) were also assessed. Serum IL-23 levels were measured in the studied groups. Results The study included 23(46%) females and 27 (54%) males with a mean age of 42.78±12.33 years. The mean serum IL-23 level was significantly higher in PsA patients (50.89±13.86 pg/ml) than in controls (43.88±6.34 pg/ml) (p=0.006). There were significant correlations between serum IL-23 levels and different grades of DAPSA activity (p=0.007) and PASI (p=0.015). No significant correlations could be detected between serum IL-23 levels and (HAQ-DI, DLQI, SF-36 or PsAQoL). CPDAI and DAPSA were significantly correlated with DLQI, SF-36 and PsAQoL. Conclusion IL-23 is a useful biomarker for identifying joint activity or skin severity but not QoL or physical function.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Interleukin 23 in Psoriatic Arthritis Patients: Relation to disease activity, physical function and health related quality of life

Elsawy

Helal

Shafei

et al. 2019

Aktuelle Rheumatologie

View full text Add to dashboard Cite

show abstract

“…38 These agents target specific components of the immune system that are essential for the generation and maintenance of the pathogenetic process. 3,9 Their appearance on the therapeutic scene has considerably changed the approach to PsA treatment.…”

Section: Biological Dmardsmentioning

confidence: 99%

“…TNFi have been approved for PsA patients since the 2000s. 3 Evidence of their efficacy in treating both PsO and PsA is available from numerous randomized controlled trials (RCTs), being significantly more effective than placebo in improving American College of Rheumatology 20% (ACR20) response rates, PsA Response Criteria (PsARC), and Psoriasis Area Severity Index (PASI). 42,46 An improvement in nail disease, dactylitis, and enthesitis, as well as a significant inhibition of radiographic progression were also detected.…”

Section: Tnf-inhibitorsmentioning

confidence: 99%

“…42,46 An improvement in nail disease, dactylitis, and enthesitis, as well as a significant inhibition of radiographic progression were also detected. 3 TNFi are also considered a first-line option for the treatment of axial disease in PsA, despite most of data being based on literature from Ankylosing Spondylitis (AS) and axial spondyloarthritis. 47 Data concerning head-to-head efficacy are still lacking, but all the drugs in the TNFi group have been indirectly compared to each other, demonstrating similar outcomes and safety profiles.…”

Section: Tnf-inhibitorsmentioning

confidence: 99%

“…2 Recent evidence suggests a complex interplay between genetic predisposition and innate and acquired immune response. 2,3 In the 1990s, findings based on the immunopathogenesis of the disease have led to the development of biological drugs directed against pathogenetic targets, such as Tumor Necrosis Factor (TNF). 4 TNF is a pleiotropic cytokine which regulates several inflammatory reactions and immune functions through the control of cellular processes and plays a central role in the pathogenesis of PsA.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

<p>An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis</p>

Chimenti¹,

D’Antonio²,

Conigliaro³

et al. 2020

BTT

Self Cite

View full text Add to dashboard Cite

Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy typically associated with psoriasis (PsO). The pathogenesis is strictly related to the association among the presence of genetic risk alleles and innate and acquired immune response with dramatic consequences on bone remodeling. Clinically, PsA patients may present heterogenicity of articular and periarticular manifestations that may be associated with the presence of comorbidities making treatment decision challenging in patients management. The identification of patient-targeted therapies is still a critical issue. Actually, several biological and synthetic drugs are promising in terms of efficacy and safety profile. National and international treatment recommendations support clinicians in the decision of the best treatment, although they may have limits basically related to updates and different outcomes included in the clinical studies evaluated. The aim of this narrative review is therefore to give guidance for clinicians for PsA patients treatment. For this purpose, we evaluated evidence on biological therapies efficacy used for PsA treatment. Specifically, we reviewed data on biological therapies, Janus kinases (JAK) inhibitors, and drugs with a new mechanism of action that are part of the treatment pipeline. The concept of "switching" and "swapping" is also described, as well as data concerning special populations such as pregnant women and elderly patients.

show abstract

Psoriatic arthritis—What we know now?

Shah

Koschitzky

Khattri

2021

Dermatological Reviews

View full text Add to dashboard Cite

Introduction: Over the past decade, our understanding of psoriatic arthritis (PsA) as a chronic inflammatory condition with a heterogenous manifestation has vastly improved. A better understanding of pathophysiology, susceptibility, clinical features, and treatment have all warranted a comprehensive and organized review of this musculoskeletal disorder which continues to affect a growing population of the western world along with psoriasis patients.Methods: Relevant articles on PsA were retrieved through a selective search on PubMed.Discussion: By acknowledging the present state of diagnostic methods and subsequent treatment strategies, clinicians will be more equipped to identify and treat this condition while also encouraging the importance of screening those who may be susceptible based on immune, environmental, and genetic factors. This article reviews the current knowledge of PsA and addresses the areas for future research.

show abstract

An update on pathogenesis of psoriatic arthritis and potential therapeutic targets

Cited by 33 publications

References 189 publications

Serum Interleukin 23 in Psoriatic Arthritis Patients: Relation to disease activity, physical function and health related quality of life

Serum Interleukin 23 in Psoriatic Arthritis Patients: Relation to disease activity, physical function and health related quality of life

<p>An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis</p>

Psoriatic arthritis—What we know now?

Contact Info

Product

Resources

About